,4 Emerging evidence suggests that KRAS mutations, particularly the 12th glycine mutation to cysteine (G12C) variant, may drive immune evasion and metastasis in PNETs by remodeling the tumor microenvironment (TME).5 The gene discussed is KRAS; the disease is neoplasm.